Marcello Albanesi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1248996/publications.pdf

Version: 2024-02-01

21 203 6 14
papers citations h-index g-index

22 22 22 334

times ranked

citing authors

docs citations

all docs

#	Article	IF	CITATIONS
1	Tumor Infiltrating T Cell Assay. Methods in Molecular Biology, 2021, 2325, 41-54.	0.9	1
2	Dupilumab elicits a favorable response in type-2 inflammatory comorbidities of severe atopic dermatitis. Clinical and Molecular Allergy, 2021, 19, 9.	1.8	1
3	Duration of chronic spontaneous urticaria remission after omalizumab discontinuation: A long-term observational study. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 2482-2485.e2.	3.8	4
4	Safety and treatment compliance of subcutaneous immunotherapy: A 30-year retrospective study. Respiratory Medicine, 2020, 161, 105843.	2.9	17
5	Safety of measles, mumps, and rubella vaccine in egg allergy: in vivo and in vitro management. Clinical and Molecular Allergy, 2020, 18, 21.	1.8	3
6	Benralizumab improves patient reported outcomes and functional parameters in difficult-to-treat patients with severe asthma: Data from a real-life cohort. Pulmonary Pharmacology and Therapeutics, 2020, 64, 101974.	2.6	10
7	Costâ€effectiveness of grass pollen allergen immunotherapy in adults. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 2319-2329.	5.7	21
8	Planned omalizumab discontinuation in CSU management as a sustainable strategy: A 2â€year realâ€life study. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 2681-2684.	5.7	4
9	Desensitization in Iron Product Allergy. Acta Haematologica, 2020, 143, 496-499.	1.4	4
10	Maintenance-Phase Subcutaneous Immunotherapy with House Dust Mites Induces Cyclic Immunologic Effects. International Archives of Allergy and Immunology, 2019, 179, 37-42.	2.1	3
11	Immunological characterization of onion (Allium cepa) allergy. Postepy Dermatologii I Alergologii, 2019, 36, 98-103.	0.9	7
12	Is immunotherapy with fungal vaccines effective?. Current Opinion in Allergy and Clinical Immunology, 2019, 19, 646-653.	2.3	5
13	Mast cells and cancer. Giornale Italiano Di Dermatologia E Venereologia, 2019, 154, 650-668.	0.8	13
14	Delayed allergy to acyclovir revealed by lymphocyte proliferation test. Postepy Dermatologii I Alergologii, 2018, 35, 527-529.	0.9	4
15	Rapid desensitization for brentuximab vedotin (Adceteris \hat{A}^{\otimes}) allergy: a case report. Clinical and Molecular Allergy, 2018, 16, 22.	1.8	6
16	A desensitization protocol for delayed allergy to cytarabine: analysis of two cases. Postepy Dermatologii I Alergologii, 2018, 35, 222-224.	0.9	3
17	Efficacy and safety of allergen immunotherapy in patients with allergy to molds: A systematic review. Clinical and Experimental Allergy, 2018, 48, 1391-1401.	2.9	14
18	A 13-year real-life study on efficacy, safety and biological effects of Vespula venom immunotherapy. Clinical and Molecular Allergy, 2018, 16, 2.	1.8	10

#	Article	IF	CITATIONS
19	Importance of Specific IgE/Total IgE Ratio in Disambiguating Amoxicillin Allergy Diagnosis in a Real-Life Setting. International Archives of Allergy and Immunology, 2018, 177, 167-169.	2.1	O
20	Desensitization for immediate hypersensitivity to oral dimethyl fumarate (Tecfidera). Journal of Allergy and Clinical Immunology: in Practice, 2017, 5, 821-822.	3.8	6
21	Long-term "real-life―safety of omalizumab in patients with severe uncontrolled asthma: A nine-year study. Respiratory Medicine, 2017, 130, 55-60.	2.9	67